Nyxoah Financials - Benzinga

Nyxoah SA

NYXHNASDAQ

Trade with Public

Trade with Public

$1.43

-0.05-3.38%

Ult. Agg.: Sep 22, 9:16 AM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Confronta Rapporto azionario

Nyxoah Financials

Nyxoah (NYXH) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Nyxoah Lowers FY2026 Sales Guidance from $42.156M-$46.840M to $41.852M-$46.502M vs $44.410M Est

Nyxoah (NASDAQ:NYXH) lowers FY2026 sales outlook from $42.156 million-$46.840 million to $41.852 million-$46.502 million vs $44.410 million estimate.

Benzinga Newsdesk

PRO
Nyxoah Q2 EPS $(0.67) Misses $(0.47) Estimate, Sales $8.922M Miss $9.030M Estimate

Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.47) by 42.55 percent. This is a 8.06 percent decrease over losses of $(0.62) per share from the same

Benzinga Newsdesk

PRO
Nyxoah Reports Preliminary Q2 Global Net Revenue Of ~€7.7M, Reiterates FY26 Global Net Revenue Range €36M - €40M

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through

Benzinga Newsdesk

PRO
Nyxoah Sees FY2026 Sales $42.156M-$46.840M vs $37.200M Est

Nyxoah (NASDAQ:NYXH) sees FY2026 sales of $42.156 million-$46.840 million vs $37.200 million analyst estimate.

Benzinga Newsdesk

PRO
Nyxoah Q1 EPS $(0.43) Beats $(0.54) Estimate, Sales $7.462M Beat $7.130M Estimate

Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 31.75 percent increase over losses of $(0.63) per share from the same

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved